. Corticosteroid-induced geographic ulceration in immunised rabbits was not prevented by concurrent HGG therapy. The findings indicate that HGG is unlikely to represent a useful therapy for ulcerative herpetic keratitis but that it may be valuable in primary disease and in long-term prophylaxis.
The pathogenesis of ulcerative herpetic keratitis is due to active proliferation of herpes simplex virus (HSV) in exposed ulcers of the corneal epithelium, where virus particles and infected cells may be relatively accessible to topically administered anti-HSV antibody. Free particles in the tear film could also be neutralised by antibody, preventing reinfection. Human gammaglobulin has been used in the treatment of herpetic keratitis,1-3 but to our knowledge no controlled experimental studies of the value of gammaglobulin in ulcerative herpetic keratitis have been reported.
Normal human gammaglobulin contains a proportion of anti-HSV antibodies, but a higher antibody titre is found in specific hyperimmune gammaglobulin (HGG) . In (Fig. 1 ).
EARLY DISEASE IN IMMUNISED A N I M A L S
No significant effect of HGG was found in immunised animals. No increase in the CID50 value was produced by HGG treatment, and no differences were found between areas of ulceration in HGG-and placebo-treated eyes on day 2, although on day 4, 2 of 4 rabbits showed a reduction in area of ulceration (Table 1) .
CORTICOSTEROID-INDUCED DISEASE IN IMMUNISED ANIMALS
No effect of HGG was found, even at the time of maximum corticosteroid-induced increase in ulceration, 7 days after the inoculation of virus and commencement of HGG treatment (Table 1 , Fig. 2 ).
Discussion
These findings show that topical HGG therapy is effective in a rabbit model of ulcerative herpetic keratitis when administered to normal It may be concluded that, although HGG has imals; areas of ulceration (% of cornea) on day 7. the advantage of low toxicity and low cost, the limitations to its efficacy shown in the present imals at an early stage in the disease process study indicate that it is unlikely to be a useful d that this effect is related to the anti-HSV therapeutic agent. However, it may be valuable tibody content of the preparation. However, in primary disease and as a long-term prophytreatment is delayed until the infection has lactic in immunosuppressed patients. become established, it has a greatly reduced efficacy, which does not compare favourably with that of established antiviral substances in this model.7 HGG has no significant effect on disease in immunised rabbits, nor does it inhibit the enhancement of ulceration which results from corticosteroid treatment in immunised animals. These findings suggest that HGG therapy would kave little value in the majority of clinical cases of ulcerative herpetic keratitis which present as established disease in patients with immune responses to the virus. The lack of effect in steroid enhanced ulceration indicates that HGG cannot be used as 'cover' for corticosteroid treatment. Although it has been reported that topical human gammaglobulin can be useful in the treatment of ulcerative and stromal herpetic keratitis,2 3 the preparation has not become generally accepted as a worthwhile therapy.
The considerable efficacy of HGG administered early in infection in normal rabbits shows that it could be a valuable nontoxic prophylactic agent, especially when immune responses are absent or deficient. Corneal infection following primary herpes simplex blepharoconjunctivitis, and the severe herpetic keratitis to which immunodeficient and immunosuppressed patients 
